Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences
Open Access
- 11 September 2022
- journal article
- research article
- Published by Wiley in JEADV Clinical Practice
- Vol. 1 (4) , 355-363
Abstract
Background: Clinical trials with dupilumab in atopic dermatitis (AD) patients showed a trend towards better effectiveness with a weekly or biweekly dosing interval, compared with extended dosing intervals. However, literature about adjusted dose regimens in daily practice is lacking.Objectives: To evaluate adjusted dosing intervals of dupilumab for AD in daily practice.Methods: An observational, longitudinal cohort study was conducted in AD patients who started dupilumab treatment in daily practice. Dosing intervals were adjusted upon shared decision making between physicians and patients in daily practice, without strict criteria. Disease courses of patients with shortened or extended dosing intervals were illustrated using spaghetti plots. In addition, data of patients who were treated with standard or extended dosing intervals were analysed using linear mixed effect (LME) models to determine the estimated effectiveness of extended dosing regimens.Results: In total, 180 AD consecutive patients treated with dupilumab in daily practice were included in our study. Patients with an extended dosing interval (n = 28) had relatively low Eczema Area and Severity Index (EASI) scores at the time of interval adjustment (range: 0−7) and the majority of patients showed continuous effectiveness after adjustment. In patients with a shortened dosing interval (n = 26), the scores at the time of adjustment were more widespread (range: 0−34) and follow‐up showed variable disease courses. Based on the LME model, we found an overall continuous improvement of EASI scores in time, in patients with a regular and extended interval.Conclusions: Patients with extended dosing intervals showed sustained effectiveness, similar to patients with standard dosing intervals. The effects of shortened intervals on disease severity could not be adequately analysed due to methodological limitations in this retrospective study.Keywords
This publication has 21 references indexed in Scilit:
- Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)British Journal of Dermatology, 2017
- Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility StudyTherapeutic Drug Monitoring, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete ClearanceActa Dermato-Venereologica, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Atopic dermatitisThe Lancet, 2016
- Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational StudyActa Dermato-Venereologica, 2016
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialThe Lancet, 2016
- An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatmentJournal of the European Academy of Dermatology and Venereology, 2012
- Atopic DermatitisNew England Journal of Medicine, 2008